Receipt of intravenous iron and clinical outcomes among hemodialysis patients hospitalized for infection

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 10, 2015, Pages 1799-1805

  Ishida, Julie H ^a,b   Marafino, Ben J ^a   McCulloch, Charles E ^a   Dalrymple, Lorien S ^c   Dudley, R Adams ^a   Grimes, Barbara A ^a   Johansen, Kirsten L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; ADVERSE EFFECTS; AGED; ANEMIA; BACTEREMIA; BLOOD VESSEL GRAFT; CATHETER INFECTION; CAUSE OF DEATH; COMPLICATION; EPIDEMIOLOGY; ERYTHROCYTE TRANSFUSION; FACTUAL DATABASE; FEMALE; HOSPITAL READMISSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; BACTEREMIA; CATHETER-RELATED INFECTIONS; CAUSE OF DEATH; DATABASES, FACTUAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES; VASCULAR GRAFTING;

EID: 84943780049     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01090115     Document Type: Article

References (22)

1. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012
2. Fishbane S: Review of issues relating to iron and infection. Am J Kidney Dis 34[Suppl 2]: S47-S52, 1999
3. Sunder-Plassmann G, Patruta SI, Hö rl WH: Pathobiology of the role of iron in infection. AmJ KidneyDis 34[Suppl 2]: S25-S29, 1999
4. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fèd'Ostiani C, Bistoni F, Romani L: Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 175: 1467-1476, 1997
5. Khan FA, Fisher MA, Khakoo RA: Association of hemochromatosiswith infectious diseases: Expanding spectrum. Int J InfectDis 11: 482-487, 2007
6. Boelaert JR, Fenves AZ, Coburn JW: Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry. Am J Kidney Dis 18: 660-667, 1991
7. Ishida JH, Johansen KL: Iron and infection in hemodialysis patients. Semin Dial 27: 26-36, 2014
8. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology: Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl 74[S110]: S7-S11, 2008
9. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, SuzukiM, Nakai S, HattoriM, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14: 240-275, 2010
10. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hö rl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1-ii47, 2004
11. US Renal Data System: Researcher's Guide, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
12. Hirth RA, Turenne MN, Wheeler JR, Nahra TA, Sleeman KK, Zhang W, Messana JA: The initial impact of Medicare's new prospective payment system for kidney dialysis. Am J Kidney Dis 62: 662-669, 2013
13. BrookhartMA, Freburger JK, Ellis AR,Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24: 1151-1158, 2013
14. Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA: Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: A replication study. BMC Nephrol 15: 154, 2014
15. Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, MichelsWM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM,Shafi T, Jaar BG,Meyer K, Ebony Boulware L; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators: Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: A comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant 30: 667- 675, 2015
16. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, EphraimPL, MichelsWM, Jaar BG, CrewsDC, Scialla JJ, Sozio SM, Shafi T,Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators: Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 9: 1930-1939, 2014
17. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87: 162-168, 2015
18. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000
19. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J AmSoc Nephrol 18: 975-984, 2007
20. Bordin JO, Heddle NM, Blajchman MA: Biologic effects of leukocytes present in transfused cellular blood products. Blood 84: 1703-1721, 1994
21. Klein HG: Immunologic aspects of blood transfusion. Semin Oncol 21[Suppl 3]: 16-20, 1994
22. Leffell MS, Kim D, Vega RM, Zachary AA, Petersen J, Hart JM, Rossert J, Bradbury BD: Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation 97: 525-533, 2014